Products found to contain undeclared medicines
|
| |
| Canada: Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product: product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA |
| |
Health Canada announces that Roope International Trading Ltd. is recalling all lots of Taisho Pharmaceutical Pabron Gold A (Granules) from retailers because product sold without market authorization in Canada. The product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the Controlled Drugs and Substances Act. The product is labelled to contain guaifenesin, dl-methylephedrine hydrochloride, acetaminophen, chlorpheniramine maleate and caffeine that may pose a risk to health.
Please refer to the following website in Health Canada for details:
http://recalls-rappels.canada.ca/en/alert-recall/taisho-pharmaceutical-pabron-gold-granules-unlicensed-product-product-labelled-contain
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/Tuesday, Jun 11, 2024
Issued at HKT 16:00
|
| |
